Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

In the literature: February 2018.

Cervantes A.

ESMO Open. 2018 Feb 1;3(2):e000322. doi: 10.1136/esmoopen-2018-000322. eCollection 2018. No abstract available.

2.

The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer?

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, Andre T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A.

Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy064. [Epub ahead of print]

PMID:
29438451
3.

Genome Sequence of Hydrogenovibrio sp. Strain SC-1, a Chemolithoautotrophic Sulfur and Iron Oxidizer.

Neely C, Bou Khalil C, Cervantes A, Diaz R, Escobar A, Ho K, Hoefler S, Smith HH, Abuyen K, Savalia P, Nealson KH, Emerson D, Tully B, Barco RA, Amend J.

Genome Announc. 2018 Feb 1;6(5). pii: e01581-17. doi: 10.1128/genomeA.01581-17.

4.

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.

Roselló S, Papaccio F, Roda D, Tarazona N, Cervantes A.

Cancer Treat Rev. 2018 Feb;63:156-171. doi: 10.1016/j.ctrv.2018.01.001. Epub 2018 Jan 11. Review.

PMID:
29407455
5.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Jan 19. doi: 10.1007/s10637-018-0562-4. [Epub ahead of print]

PMID:
29349598
6.

Pro-inflammatory cytokines after an episode of acute pancreatitis: associations with fasting gut hormone profile.

Pendharkar SA, Singh RG, Chand SK, Cervantes A, Petrov MS.

Inflamm Res. 2017 Dec 29. doi: 10.1007/s00011-017-1125-4. [Epub ahead of print]

PMID:
29288273
7.

mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival.

García-García AB, Gómez-Mateo MC, Hilario R, Rentero-Garrido P, Martínez-Domenech A, Gonzalez-Albert V, Cervantes A, Marín-Garcia P, Chaves FJ, Ferrández-Izquierdo A, Sabater L.

Oncotarget. 2017 Aug 3;8(62):104796-104805. doi: 10.18632/oncotarget.20076. eCollection 2017 Dec 1.

8.

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.

Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotté F, Strasser F, Young A, Bruera E, Herrstedt J, Keefe D, Laird B, Walsh D, Douillard JY, Cervantes A.

Ann Oncol. 2018 Jan 1;29(1):36-43. doi: 10.1093/annonc/mdx757.

PMID:
29253069
9.

Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.

Roselló S, Frasson M, García-Granero E, Roda D, Jordá E, Navarro S, Campos S, Esclápez P, García-Botello S, Flor B, Espí A, Masciocchi C, Valentini V, Cervantes A.

Clin Colorectal Cancer. 2017 Oct 28. pii: S1533-0028(17)30212-8. doi: 10.1016/j.clcc.2017.10.014. [Epub ahead of print]

PMID:
29162332
10.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
11.

Perfusion-based human cadaveric specimen as a simulation training model in repairing cerebrospinal fluid leaks during endoscopic endonasal skull base surgery.

Christian EA, Bakhsheshian J, Strickland BA, Fredrickson VL, Buchanan IA, Pham MH, Cervantes A, Minneti M, Wrobel BB, Giannotta S, Zada G.

J Neurosurg. 2017 Nov 3:1-5. doi: 10.3171/2017.5.JNS162982. [Epub ahead of print]

PMID:
29099299
12.

Elucidating the molecular basis of PPCD: Effects of decreased ZEB1 expression on corneal endothelial cell function.

Zakharevich M, Kattan JM, Chen JL, Lin BR, Cervantes AE, Chung DD, Frausto RF, Aldave AJ.

Mol Vis. 2017 Oct 14;23:740-752. eCollection 2017.

13.

Liquid biopsy: another tool towards tailored therapy in colorectal cancer.

Tarazona N, Cervantes A.

Ann Oncol. 2018 Jan 1;29(1):7-8. doi: 10.1093/annonc/mdx641. No abstract available.

PMID:
29045545
14.

Nance-Horan syndrome in females due to a balanced X;1 translocation that disrupts the NHS gene: Familial case report and review of the literature.

Gómez-Laguna L, Martínez-Herrera A, Reyes-de la Rosa ADP, García-Delgado C, Nieto-Martínez K, Fernández-Ramírez F, Valderrama-Atayupanqui TY, Morales-Jiménez AB, Villa-Morales J, Kofman S, Cervantes A, Morán-Barroso VF.

Ophthalmic Genet. 2018 Jan-Feb;39(1):56-62. doi: 10.1080/13816810.2017.1363245. Epub 2017 Sep 18.

PMID:
28922055
15.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224. No abstract available.

PMID:
28881920
16.

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv100-iv118. doi: 10.1093/annonc/mdx216. No abstract available.

PMID:
28881914
17.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.

ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review.

18.

In the literature: April 2017.

Cervantes A.

ESMO Open. 2017 May 2;2(2):e000193. doi: 10.1136/esmoopen-2017-000193. eCollection 2017. No abstract available.

19.

In the literature: February 2017.

Cervantes A, Terol MJ.

ESMO Open. 2017 Mar 24;2(1):e000171. doi: 10.1136/esmoopen-2017-000171. eCollection 2017. No abstract available.

20.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

PMID:
28600476
21.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

Oncologist. 2017 Sep;22(9):1024-e89. doi: 10.1634/theoncologist.2017-0175. Epub 2017 Jun 7.

22.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

23.

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F.

Ann Oncol. 2017 Aug 1;28(8):1713-1729. doi: 10.1093/annonc/mdx175.

PMID:
28407110
24.

Meta-analysis of effects of inoculation with homofermentative and facultative heterofermentative lactic acid bacteria on silage fermentation, aerobic stability, and the performance of dairy cows.

Oliveira AS, Weinberg ZG, Ogunade IM, Cervantes AAP, Arriola KG, Jiang Y, Kim D, Li X, Gonçalves MCM, Vyas D, Adesogan AT.

J Dairy Sci. 2017 Jun;100(6):4587-4603. doi: 10.3168/jds.2016-11815. Epub 2017 Mar 23.

25.

Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results.

Flor-Lorente B, Báguena G, Frasson M, García-Granero A, Cervantes A, Sanchiz V, Peña A, Espí A, Esclapez P, García-Granero E.

Cir Esp. 2017 Mar;95(3):143-151. doi: 10.1016/j.ciresp.2016.12.014. Epub 2017 Mar 21. English, Spanish.

PMID:
28336185
26.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

27.

Vortex Pattern of Corneal Deposits in Granular Corneal Dystrophy Associated With the p.(Arg555Trp) Mutation in TGFBI.

Kattan JM, Serna-Ojeda JC, Sharma A, Kim EK, Ramirez-Miranda A, Cruz-Aguilar M, Cervantes AE, Frausto RF, Zenteno JC, Graue-Hernandez EO, Aldave AJ.

Cornea. 2017 Feb;36(2):210-216. doi: 10.1097/ICO.0000000000001045.

28.

Confirmation of the OVOL2 Promoter Mutation c.-307T>C in Posterior Polymorphous Corneal Dystrophy 1.

Chung DD, Frausto RF, Cervantes AE, Gee KM, Zakharevich M, Hanser EM, Stone EM, Heon E, Aldave AJ.

PLoS One. 2017 Jan 3;12(1):e0169215. doi: 10.1371/journal.pone.0169215. eCollection 2017.

29.

Mutational spectrum of EDA and EDAR genes in a cohort of Mexican mestizo patients with hypohidrotic ectodermal dysplasia.

Monroy-Jaramillo N, Abad-Flores JD, García-Delgado C, Villaseñor-Domínguez A, Mena-Cedillos C, Toledo-Bahena ME, Valencia-Herrera AM, Sánchez-Boiso A, Akaki-Carreño YI, Del Río Navarro B, Aguirre-Hernández J, López-López M, Cervantes A, Cerbón M, Morán-Barroso VF.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):e321-e324. doi: 10.1111/jdv.14107. Epub 2017 Feb 17. No abstract available.

PMID:
28045201
30.

Fate of Escherichia coli O157:H7 and bacterial diversity in corn silage contaminated with the pathogen and treated with chemical or microbial additives.

Ogunade IM, Jiang Y, Kim DH, Cervantes AAP, Arriola KG, Vyas D, Weinberg ZG, Jeong KC, Adesogan AT.

J Dairy Sci. 2017 Mar;100(3):1780-1794. doi: 10.3168/jds.2016-11745. Epub 2016 Dec 29.

PMID:
28041727
31.

In the literature: October 2016.

Cervantes A.

ESMO Open. 2016 Oct 18;1(5):e000103. eCollection 2016. No abstract available.

32.

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A.

Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21.

33.

In the literature: May 2016.

Cervantes A.

ESMO Open. 2016 May 25;1(3):e000071. eCollection 2016. No abstract available.

34.

In the literature: March 2016.

Cervantes A.

ESMO Open. 2016 Mar 16;1(2):e000046. eCollection 2016. No abstract available.

35.

In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.

Riffo-Campos ÁL, Castillo J, Vallet-Sánchez A, Ayala G, Cervantes A, López-Rodas G, Franco L.

Oncol Rep. 2016 Dec;36(6):3627-3634. doi: 10.3892/or.2016.5210. Epub 2016 Oct 27.

PMID:
27805251
36.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T.

Dig Liver Dis. 2016 Nov;48(11):1283-1289. doi: 10.1016/j.dld.2016.08.112. Epub 2016 Aug 20.

PMID:
27590840
37.

Erratum to «Non-surgical treatment of localized rectal cancer is an experimental option».

Roselló S, Cervantes A.

Cir Esp. 2016 Dec;94(10):617. doi: 10.1016/j.ciresp.2016.07.003. Epub 2016 Sep 22. English, Spanish. No abstract available.

PMID:
27665962
38.

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. No abstract available.

PMID:
27664260
39.

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A.

Breast Cancer Res Treat. 2016 Nov;160(1):69-77. Epub 2016 Sep 14.

PMID:
27628192
40.

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.

Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.

Oncotarget. 2016 Sep 27;7(39):63424-63436. doi: 10.18632/oncotarget.11520.

41.

MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.

Fleitas T, Ibarrola-Villava M, Ribas G, Cervantes A.

Cancer Treat Rev. 2016 Sep;49:57-64. doi: 10.1016/j.ctrv.2016.07.007. Epub 2016 Jul 29. Review.

PMID:
27501018
42.

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.

Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R.

Clin Transl Oncol. 2017 Feb;19(2):227-235. doi: 10.1007/s12094-016-1528-7. Epub 2016 Jul 21.

43.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Carcinogenesis. 2016 Sep;37(9):852-7. doi: 10.1093/carcin/bgw073. Epub 2016 Jul 5.

44.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
45.

Treatment sequence of synchronously (liver) metastasized colon cancer.

Gruenberger T, Beets G, Van Laethem JL, Rougier P, Cervantes A, Douillard JY, Figueras J, Gruenberger B, Haller DG, Labianca R, Maleux G, Roth A, Ducreux M, Schmiegel W, Seufferlein T, Van Cutsem E.

Dig Liver Dis. 2016 Oct;48(10):1119-23. doi: 10.1016/j.dld.2016.06.009. Epub 2016 Jun 17. Review.

PMID:
27375207
46.

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.

Breugom AJ, Bastiaannet E, Boelens PG, Iversen LH, Martling A, Johansson R, Evans T, Lawton S, O'Brien KM, Van Eycken E, Janciauskiene R, Liefers GJ, Cervantes A, Lemmens VE, van de Velde CJ.

Eur J Cancer. 2016 Aug;63:110-7. doi: 10.1016/j.ejca.2016.04.017. Epub 2016 Jun 11.

PMID:
27299663
47.

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I.

Ann Oncol. 2016 Aug;27(8):1557-65. doi: 10.1093/annonc/mdw215. Epub 2016 May 23.

PMID:
27217542
48.

Personalised Treatment in Gastric Cancer: Myth or Reality?

Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A.

Curr Oncol Rep. 2016 Jul;18(7):41. doi: 10.1007/s11912-016-0525-x. Review.

PMID:
27215435
49.

Non-surgical treatment of localized rectal cancer is an experimental option.

Roselló S, Cervantes A.

Cir Esp. 2016 Jun-Jul;94(6):311-2. doi: 10.1016/j.ciresp.2016.03.003. Epub 2016 Apr 26. English, Spanish. No abstract available.

PMID:
27130214
50.

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A.

Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.

Supplemental Content

Loading ...
Support Center